PT - JOURNAL ARTICLE AU - Hossein Jadvar AU - Patrick M. Colletti TI - Clinical Trials of Prostate-Specific Membrane Antigen Radiopharmaceutical Therapy AID - 10.2967/jnmt.122.264928 DP - 2023 Mar 01 TA - Journal of Nuclear Medicine Technology PG - 16--21 VI - 51 IP - 1 4099 - http://tech.snmjournals.org/content/51/1/16.short 4100 - http://tech.snmjournals.org/content/51/1/16.full SO - J. Nucl. Med. Technol.2023 Mar 01; 51 AB - Prostate-specific membrane antigen (PSMA) theranostics has been a momentous triumph for nuclear medicine. The recent approvals of PSMA-targeted imaging agents (68Ga-PSMA-11, 18F-DCFPyL) and radiopharmaceutical therapy (177Lu-PSMA-617) have paved the way for theranostics as a viable care strategy for men with metastatic castration-resistant prostate cancer. The imaging clinical trials OSPREY, CONDOR, and those conducted at the University of California (Los Angeles and San Francisco), as well as the randomized phase 3 therapy trial VISION, have been the fruitful beginnings for PSMA theranostics. There are currently several ongoing clinical trials to expand the reach of PSMA theranostics to the earlier phases of prostate cancer and to optimize its utility in combination therapeutic regimens. We provide a brief narrative review of the many PSMA-directed radiopharmaceutical therapy clinical trials with the β-emitter 177Lu-PSMA-617 and the α-emitter 225Ac-PSMA-617 in prostate cancer.